Detalles de la búsqueda
1.
Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II 'proof-of-concept' iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network.
Eur J Cancer
; 117: 121-130, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31279304
Resultados
1 -
1
de 1
1
Próxima >
>>